If weight has come back every time despite genuine effort, that is not a character flaw. It is physiology doing exactly what it evolved to do — and it is the reason medical treatment exists.
Why weight comes back
After weight loss, the body defends its previous weight: appetite hormones shift, satiety signals weaken, and energy expenditure adapts downward. This is not willpower failing. It is a regulatory system working against a deliberate deficit, and it is why regain is the rule rather than the exception with diet alone.
What the trial data actually shows
In the SURMOUNT-1 trial — 2,539 adults across nine countries including India — participants on tirzepatide had mean weight loss of 16.0% at 5 mg, 21.4% at 10 mg and 22.5% at 15 mg at 72 weeks, versus 2.4% on placebo.
Looking at thresholds rather than averages: at 72 weeks, 73–90% of participants achieved at least 10% weight reduction depending on dose, and 32–63% achieved at least 20%.
Those are trial numbers under trial conditions. Real-world results vary with dose tolerance, adherence, and what happens alongside the medicine.
What a proper programme includes — and what it isn’t
The prescription is one component. On its own it is not a programme.
- Eligibility assessment. BMI, metabolic profile, medical history, current medicines, and any condition that makes treatment unsuitable. Not everyone is a candidate, and it is our job to say so.
- Baseline investigations where indicated, so we are treating a known picture rather than a guess.
- Gradual dose escalation under review — the single biggest determinant of whether side effects are tolerable.
- Protein-adequate nutrition and resistance training to protect lean mass. Weight loss without this costs you muscle you will want back.
- Monitoring of weight, body composition, measurements and vitals — not just the number on a scale.
- A maintenance and tapering strategy planned from the beginning, because what happens after matters as much as what happens during.
Side effects, stated plainly
The common ones are gastrointestinal: nausea, reduced appetite (which is also the therapeutic effect), and altered bowel habit. They are usually most noticeable early and after each dose increase, and they are the reason escalation is slow and supervised rather than fast. Serious adverse effects are uncommon but real, which is why this is a prescription medicine requiring medical oversight — never a product to source independently.
This may suit you if
- Your BMI is in the treatment range, or lower with a weight-related condition
- You have lost and regained weight despite genuine, sustained effort
- You want medical supervision, monitoring and follow-up — not a product
- You are willing to pair treatment with nutrition and activity changes
Important to know
These are prescription medicines. In India, prescription drugs cannot be advertised to the public, so this article deliberately describes the programme and the published evidence rather than promoting any specific product. Suitability, dosing and the treatment itself are decided only in consultation, after assessment by Dr. Sarat Anandh, MD DVL.
Not suitable in several situations, including type 1 diabetes, a history of pancreatitis, and pregnancy or planned pregnancy. These are discussed individually before anything begins.
- SURMOUNT-1 results published in the New England Journal of Medicine (Eli Lilly)
- Tirzepatide delivered up to 22.5% weight loss in SURMOUNT-1
- Weight reduction over time by early weight-loss response: SURMOUNT-1 post hoc analysis
This article is general information, not medical advice, and it isn’t a substitute for examination. Individual results vary. Any treatment mentioned is undertaken only after consultation and assessment by Dr. Sarat Anandh, MD DVL.